Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

At Home Use of Noninvasive Vagus Nerve Stimulation Following TBI to Improve Cognition.

16 november 2026 uppdaterad av: Elliot Roth, Shirley Ryan AbilityLab

Randomized, Sham-controlled Clinical Trial Testing At-home Use of Noninvasive Vagus Nerve Stimulation After TBI

The purpose of this study is to evaluate whether individuals with TBI can comfortably and consistently use transcutaneous vagus nerve stimulation (tVNS) at home and to identify barriers that may affect participation. A secondary objective is to obtain preliminary data to examine whether at-home tVNS is associated with improvement in cognitive skills as well as any improvement in patient reported outcomes such as sleep, mood, or fatigue.

Studieöversikt

Detaljerad beskrivning

This is a sham controlled pilot study to evaluate the feasibility and preliminary efficacy of remotely supervised, at-home delivery of tVNS in individuals with TBI during the post-acute recovery phase. Eligible participants will complete a 4-week tVNS intervention protocol at home. Mixed methods (quantitative and qualitative) will be used to evaluate outcomes. Eligible participants will be invited to initial baseline assessment and tVNS training session (Visit 1). Then, they will be randomly allocated to recieve either active or sham stimulation for the first two weeks of at-home administration period. They will then return for a min-intervention assessment (Visit 2). After the mid-intervention assessment, they will return home and recieve active stimulation for the remaining two weeks. Lastly, they will return to a post- intervention assessment (Visit 3). In the assessment sessions participants will complete tasks of set shifting and working memory, core executive functions, as well as complete surveys regarding fatigue, sleep, and overall quality of life.

Studietyp

Interventionell

Inskrivning (Beräknad)

30

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Rekrytering
        • Shirley Ryan AbilityLab
      • Chicago, Illinois, Förenta staterna, 60611
        • Har inte rekryterat ännu
        • Shirley Ryan AbilityLab
        • Huvudutredare:
          • Elliot Roth, MD
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 18-75 years Formally diagnosed with traumatic brain injury.
  • Ability to independently use a keyboard.
  • Ability to independently apply the electrode and adjust stimulation or have a designated caregiver available to be trained and assist with these tasks.
  • Able to understand and communicate in English (according to clinical judgment).
  • Able to independently provide consent to participate. -Able to come in person to Shirley Ryan AbilityLab in Chicago, IL for three visits over 5 weeks.

Exclusion Criteria:

  • Acute medical issues requiring close physician or nursing monitoring. Bioelectrical implants, cerebral shunts, including pacemakers.
  • Anyone with sore or diseased skin area in the ear
  • Pregnancy or persons who are lactating.
  • Cardiac arrhythmia.
  • Epilepsy or seizure disorders.
  • Significant gross or fine motor weakness.
  • Significant, ongoing communication or comprehension impairments (such as aphasia) that would affect an individual's ability to complete the required assessments.
  • Severely impaired memory retention
  • Current major depression diagnosis.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Active Stimulation

Initial baseline assessment completed Day 0. Active stimulation using Tancutaneous Vagus Nerve Stimulation (tVNS) device , for atleast one hour a day for 14 days at home (Day1-14). A mid intervention assessment session completed on Day 15. Following that assessment, another two weeks (Day 16-29) of active stimulation at home followed by a post intervention assessment session.

tVNS stimulation at home for atleast one hour a day for 4 weeks.

Sham Comparator: Sham Stimulation

Initial baseline assessment completed Day 0. Sham stimulation using Tancutaneous Vagus Nerve Stimulation (tVNS) device, for atleast one hour a day for 14 days at home (Day1-14). A mid intervention assessment session completed on Day 15. Following that assessment, participant will switch to recieve active stimulation for the remaining 2 week at home (Day 16-29) followed by a post intervention assessment session.

Participants will recieve two weeks of sham stimulation for atleast one hour a day, followed by 2 weeks of active stimulation for atleast one hour a day.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Recording the number of participant who completed at least 75% of the sessions out of the number of participants enrolled in the study.
Tidsram: Post Intervention Assessment Day 30
Post Intervention Assessment Day 30
Semi-structured interviews will collect feedback on perceived benefit, usability, logistical challenges, and barriers to adherence.
Tidsram: Post Intervention Assessment Session Day 30
Post Intervention Assessment Session Day 30

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
N-Back
Tidsram: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

In the N-Back Task, participants are presented a series of visual stimuli. They are asking for each stimulus whether is matches a stimulus n-trials before. For example, in a 2-back task, in which the trials consist of letters, participants have to decide whether the current letter is the same as the letter in the trial n-2. We will use a computerized version of this task.

Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
California Verbal Learning Test
Tidsram: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

The California Verbal Learning Test evaluates the ability to encode, recall, and recognize verbally presented information across multiple learning trials and delayed recall conditions. Participants are read multiple lists of words and asked to recall specific words at different time allotments.

Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
Trail Making A&B
Tidsram: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

Trail Making Part A requires participant to draw a line between circles containing numbers in ascending order. Part B requires participants to alternate drawing a line between ascending letters and numbers. The key measures are the time required to complete and the number of errors made in Part A and Part B. The test measures various aspects of cognition including attention, visual search, motor coordination, reasoning, and task switching.

Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
Conners Continuous Performance Test 3rd Edition
Tidsram: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

CPT-3 is a computerized task requires of pressing the space bar on a computer keyboard after any letter is presented on the screen, except for the letter "X". This test lasts about 14 minutes. It measures several aspects of sustained attention, including inattention, impulsivity, and vigilance captured by measuring response styles, errors, and response times.

Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 december 2026

Primärt slutförande (Beräknad)

1 december 2028

Avslutad studie (Beräknad)

1 mars 2029

Studieregistreringsdatum

Först inskickad

16 november 2026

Först inskickad som uppfyllde QC-kriterierna

16 november 2026

Första postat (Faktisk)

20 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera